IRIS UniCatt

Coratti, Giorgia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.283
EU - Europa 5.692
AS - Asia 5.292
SA - Sud America 1.014
AF - Africa 147
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 6
Totale 18.445
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.982
SG - Singapore 2.526
IT - Italia 1.378
DE - Germania 1.261
CN - Cina 1.023
BR - Brasile 796
NL - Olanda 783
SE - Svezia 609
VN - Vietnam 547
FR - Francia 459
IE - Irlanda 258
GB - Regno Unito 220
JP - Giappone 184
IN - India 177
CA - Canada 163
HK - Hong Kong 144
BD - Bangladesh 138
FI - Finlandia 136
ID - Indonesia 131
RU - Federazione Russa 105
PL - Polonia 100
AR - Argentina 84
MX - Messico 75
ES - Italia 72
TR - Turchia 71
KR - Corea 68
IQ - Iraq 52
AT - Austria 48
ZA - Sudafrica 44
UA - Ucraina 40
EC - Ecuador 34
CZ - Repubblica Ceca 31
PK - Pakistan 30
BE - Belgio 28
CH - Svizzera 27
VE - Venezuela 25
IR - Iran 24
LT - Lituania 24
CO - Colombia 23
PH - Filippine 23
IL - Israele 18
PA - Panama 18
PY - Paraguay 18
RO - Romania 18
SA - Arabia Saudita 18
AE - Emirati Arabi Uniti 17
EG - Egitto 16
MA - Marocco 16
RS - Serbia 15
UZ - Uzbekistan 15
CI - Costa d'Avorio 14
TN - Tunisia 14
JO - Giordania 13
MK - Macedonia 13
PE - Perù 13
KE - Kenya 11
PT - Portogallo 11
CL - Cile 10
CR - Costa Rica 8
DO - Repubblica Dominicana 8
NP - Nepal 8
BG - Bulgaria 7
DK - Danimarca 7
JM - Giamaica 7
KZ - Kazakistan 7
MY - Malesia 7
OM - Oman 7
NZ - Nuova Zelanda 6
UY - Uruguay 6
AL - Albania 5
HN - Honduras 5
LK - Sri Lanka 5
NG - Nigeria 5
SK - Slovacchia (Repubblica Slovacca) 5
SV - El Salvador 5
TH - Thailandia 5
AU - Australia 4
BY - Bielorussia 4
DZ - Algeria 4
ET - Etiopia 4
HU - Ungheria 4
KG - Kirghizistan 4
LV - Lettonia 4
SN - Senegal 4
TW - Taiwan 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AZ - Azerbaigian 3
BH - Bahrain 3
BO - Bolivia 3
GE - Georgia 3
GR - Grecia 3
GT - Guatemala 3
LA - Repubblica Popolare Democratica del Laos 3
LB - Libano 3
LU - Lussemburgo 3
ME - Montenegro 3
XK - ???statistics.table.value.countryCode.XK??? 3
AO - Angola 2
BA - Bosnia-Erzegovina 2
BT - Bhutan 2
Totale 18.402
Salva come PNG Salva come JPEG
Città #
Singapore 1.544
Ashburn 846
Amsterdam 704
San Jose 688
Chandler 597
New York 323
Rome 320
Frankfurt am Main 309
Dublin 229
Los Angeles 227
Beijing 194
Milan 189
Hefei 181
Ho Chi Minh City 180
Tokyo 177
Hong Kong 130
Hanoi 127
Lauterbourg 127
Tukwila 120
Jakarta 117
Dallas 97
Munich 91
São Paulo 88
Boston 84
Buffalo 74
Chicago 74
Helsinki 74
Warsaw 69
Marseille 68
Seoul 66
Orem 65
The Dalles 62
Santa Clara 61
Montreal 59
Princeton 58
San Mateo 56
Atlanta 54
Council Bluffs 52
Boardman 48
Houston 48
Kent 48
Moscow 48
London 44
Denver 43
Nuremberg 42
Brooklyn 41
Poplar 41
Stockholm 41
Paris 38
Toronto 38
Wilmington 38
Chennai 35
Düsseldorf 35
Da Nang 33
Palermo 33
Johannesburg 30
Bremen 28
Haiphong 28
Mexico City 28
Phoenix 28
Lappeenranta 26
Nanjing 26
Turku 25
Pune 24
Shanghai 23
Turin 23
Ann Arbor 22
Dearborn 22
Ankara 21
Brussels 21
Baghdad 20
Brno 20
Columbus 20
San Francisco 20
Vienna 20
Belo Horizonte 19
Bologna 19
Brasília 19
Fairfield 19
Rio de Janeiro 19
Biên Hòa 17
Dhaka 17
Falkenstein 17
Florence 17
Guangzhou 17
Seattle 17
Charlotte 16
Kish 15
Naples 15
New Delhi 15
Abidjan 14
Bexley 14
Hyderabad 14
Manchester 14
Querétaro 14
Redmond 14
Andover 13
Augusta 13
City of London 13
Memphis 13
Totale 10.144
Salva come PNG Salva come JPEG
Nome #
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 962
Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial 682
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 503
Oral and Swallowing Abilities Tool (OrSAT) for Type 1 SMA Patients: Development of a New Module 336
Performance of Upper Limb module for Duchenne muscular dystrophy 239
Assessing floppy infants: a new module 213
Oral and Swallowing Abilities Tool (OrSAT) in nusinersen treated patients 204
Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening 192
Developmental milestones in type I spinal muscular atrophy 190
Predictive models in SMA II natural history trajectories using machine learning: A proof of concept study 186
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey 180
Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen 177
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 173
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 170
Type I SMA “new natural history”: long-term data in nusinersen-treated patients 167
Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in naïve patients with spinal muscular atrophy and following switch from other therapies 165
Body mass index in type 2 spinal muscular atrophy: a longitudinal study 165
SMA-miRs (MiR-181a- 5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples 165
Early neurological signs in infants identified through neonatal screening for SMA: do they predict outcome? 161
SMA-miRs (MiR-181a- 5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples 161
Different trajectories in upper limb and gross motor function in spinal muscular atrophy 158
Gain and loss of upper limb abilities in Duchenne muscular dystrophy patients: A 24-month study 157
Hammersmith Infant Neurological Examination in low-risk infants born very preterm: a longitudinal prospective study 156
Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersen 155
Nusinersen in type 1 spinal muscular atrophy: Twelve-month real-world data 154
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen 152
Respiratory function and therapeutic expectations in DMD: Families experience and perspective 151
Can the CHOP-INTEND be used as An Outcome Measure in the First Months of Age? Implications for Clinical Trials and Real World Data 149
The nonsense mutation stop+4 model correlates with motor changes in Duchenne muscular dystrophy 148
Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy 147
Disease Trajectories in the Revised Hammersmith Scale in a Cohort of Untreated Patients with Spinal Muscular Atrophy types 2 and 3 146
Revised upper limb module for spinal muscular atrophy: Development of a new module 146
Upper limb function in Duchenne muscular dystrophy: 24 month longitudinal data. 146
Type I Spinal Muscular Atrophy patients treated with nusinersen: 4 year follow-up of motor, respiratory and bulbar function 143
Bulbar function in spinal muscular atrophy (SMA): State of art and new challenges. 21st July 2023, Rome, Italy 142
2-Year Change in Revised Hammersmith Scale Scores in a Large Cohort of Untreated Paediatric Type 2 and 3 SMA Participants 142
6MWT can identify type 3 SMA patients with neuromuscular junction dysfunction 142
The Spinal Muscular Atrophy Health Index: Italian validation of a disease-specific outcome measure 141
Early Gross Motor Milestones in Duchenne Muscular Dystrophy 141
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 139
Early Childhood Attention Battery: Italian adaptation and new expanded normative data. 139
Myostatin Levels in SMA Following Disease-Modifying Treatments: A Multi-Center Study 138
Longitudinal motor functional outcomes and magnetic resonance imaging patterns of muscle involvement in upper limbs in duchenne muscular dystrophy 138
A Longitudinal Follow-Up Study of Intellectual Function in Duchenne Muscular Dystrophy over Age: Is It Really Stable? 138
Type I spinal muscular atrophy and disease modifying treatments: a nationwide study in children born since 2016 138
Ambulatory function in spinal muscular atrophy: Age-related patterns of progression. 137
Early treatment of type II SMA slows rate of progression of scoliosis 135
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 135
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial 135
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 134
Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen 134
Language Development in Preschool Duchenne Muscular Dystrophy Boys 134
Timed Rise from Floor as a Predictor of Disease Progression in Duchenne Muscular Dystrophy: An Observational Study 134
Revised north star ambulatory assessment for young boys with Duchenne muscular dystrophy 133
Functional levels and MRI patterns of muscle involvement in upper limbs in Duchenne muscular dystrophy. 133
Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy 132
Prevalence of Duchenne muscular dystrophy in Italy: a nationwide survey 131
Nusinersen in pediatric and adult patients with type III spinal muscular atrophy 131
Respiratory Trajectories in Type 2 and 3 Spinal Muscular Atrophy in the iSMAC Cohort Study 131
Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53 130
Longitudinal Analysis of PUL 2.0 Domains in Ambulant and Non-Ambulant Duchenne Muscular Dystrophy Patients: How do they Change in Relation to Functional Ability? 130
An observational study of functional abilities in infants, children, and adults with type 1 SMA. 129
Early Childhood Attention Battery: Italian adaptation and new expanded normative data. 129
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey 127
A critical review of patient and parent caregiver oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in spinal muscular atrophy 127
Italian survey on evolving SMA care with disease-modifying therapies: a consensus workshop on nutrition, swallowing, respiratory and rehabilitation care 126
Assessment of early attention in an Italian cohort of preschooler preterm children using the Early Childhood Attention Battery 125
A Longitudinal Follow-Up Study of Intellectual Function in Duchenne Muscular Dystrophy over Age: Is It Really Stable? 125
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 124
High Expression of SMN circ4-2b-3 in SMA I Children Treated with Nusinersen is Associated with Improved Motor Outcomes 124
Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial 124
Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy 123
Language Development in Preschool Duchenne Muscular Dystrophy Boys 122
Body mass index in type 2 spinal muscular atrophy: a longitudinal study 122
Does albuterol have an effect on neuromuscular junction dysfunction in spinal muscular atrophy? 121
Sleep disorders in spinal muscular atrophy 118
Developmental milestones in type I spinal muscular atrophy 118
Development of an International SMA Bulbar Assessment for Inter-professional Administration 117
Longitudinal natural history in young boys with Duchenne muscular dystrophy 116
Longitudinal Motor Functional Outcomes and Magnetic Resonance Imaging Patterns of Muscle Involvement in Upper Limbs in Duchenne Muscular Dystrophy. 116
Revised upper limb module for spinal muscular atrophy: Development of a new module 115
Clinical Variability in Spinal Muscular Atrophy Type III. 114
Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis 114
Determining minimal clinically important differences in the Hammersmith Functional Motor Scale Expanded for untreated spinal muscular atrophy patients: An international study 113
An observational study of functional abilities in infants, children, and adults with type 1 SMA 112
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 111
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 111
Long‐term natural history in type II and III spinal muscular atrophy: a 4‐year international study on the Hammersmith Functional Motor Scale Expanded 108
Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis 108
Longitudinal Analysis of PUL 2.0 Domains in Ambulant and Non-Ambulant Duchenne Muscular Dystrophy Patients: How do they Change in Relation to Functional Ability? 107
Communicative development inventory in type 1 and presymptomatic infants with spinal muscular atrophy: a cohort study 107
Development of an academic disease registry for spinal muscular atrophy 107
Patient reported outcome measure for upper limb in Duchenne muscular dystrophy: correlation with PUL2.0 106
Risdiplam in Type 1 Spinal Muscular Atrophy 105
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 105
P.222Long term progression in type II spinal muscular atrophy: a retrospective observational study 103
Longitudinal natural history of type I spinal muscular atrophy: A critical review 100
Clinical Phenotype of Pediatric and Adult Patients With Spinal Muscular Atrophy With Four SMN2 Copies: Are They Really All Stable? 99
North Star Ambulatory Assessment changes in ambulant Duchenne boys amenable to skip exons 44, 45, 51, and 53: A 3 year follow up 99
Changes in abilities over the initial 12 months of nusinersen treatment for type II SMA 98
Totale 15.641
Salva come PNG Salva come JPEG
Categoria #
all - tutte 75.701
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 75.701
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022693 45 7 15 92 52 27 17 95 50 41 122 130
2022/20232.030 179 245 123 273 135 262 143 182 277 37 102 72
2023/20241.666 60 299 70 140 76 297 196 83 42 86 130 187
2024/20253.182 64 53 217 197 247 170 166 135 425 251 668 589
2025/202610.634 954 294 588 1.277 1.793 1.997 1.453 427 468 508 506 369
2026/2027144 144 0 0 0 0 0 0 0 0 0 0 0
Totale 18.687